OSM and oncostatin-M measurement: We envision that using our optimized bioactivity assay in combination with NMR chemical shift perturbations will enable a structure-based drug design approach for targeting OSM that could eventually lead to a useful therapeutic option for treatment of OSM-related illnesses.